Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4745449
Max Phase: Preclinical
Molecular Formula: C72H113N25O23S4
Molecular Weight: 1825.12
Molecule Type: Unknown
Associated Items:
ID: ALA4745449
Max Phase: Preclinical
Molecular Formula: C72H113N25O23S4
Molecular Weight: 1825.12
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CS)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)CN)C(=O)N[C@@H](CS)C(N)=O
Standard InChI: InChI=1S/C72H113N25O23S4/c1-3-34(2)55(68(118)92-46(29-121)56(74)106)95-59(109)40(16-17-53(102)103)86-67(117)51-11-6-20-96(51)69(119)42(23-36-26-79-33-82-36)88-61(111)44(27-98)90-60(110)41(22-35-12-14-37(100)15-13-35)87-57(107)38(8-4-18-80-71(75)76)84-64(114)48(31-123)93-58(108)39(9-5-19-81-72(77)78)85-66(116)50-10-7-21-97(50)70(120)43(24-54(104)105)89-62(112)45(28-99)91-65(115)49(32-124)94-63(113)47(30-122)83-52(101)25-73/h12-15,26,33-34,38-51,55,98-100,121-124H,3-11,16-25,27-32,73H2,1-2H3,(H2,74,106)(H,79,82)(H,83,101)(H,84,114)(H,85,116)(H,86,117)(H,87,107)(H,88,111)(H,89,112)(H,90,110)(H,91,115)(H,92,118)(H,93,108)(H,94,113)(H,95,109)(H,102,103)(H,104,105)(H4,75,76,80)(H4,77,78,81)/t34-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,55-/m0/s1
Standard InChI Key: CFTHWIIIZOVWJE-YUKGDWDQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1825.12 | Molecular Weight (Monoisotopic): 1823.7324 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Cai F,Xu N,Liu Z,Ding R,Yu S,Dong M,Wang S,Shen J,Tae HS,Adams DJ,Zhang X,Dai Q. (2018) Targeting of N-Type Calcium Channels via GABA-Receptor Activation by α-Conotoxin Vc1.1 Variants Displaying Improved Analgesic Activity., 61 (22): [PMID:30358401] [10.1021/acs.jmedchem.8b01343] |
Source(1):